Gelucire 5013 Gattefosse

Solubilizer for poorly-soluble APIs and bioavailability enhancer.

Gelucire 5013 gattefosse. R=C16 or C18 Schematic structures PEG1500 esters O H R -C O -O 3 3 O -C O -R R -C O -O 3 3 Phospholipon® 90G Phospholipon® 90G was received as a gift sample from Phospholipid GmbH (Nattermannalle, Germany). Development of Solid SEDDS, III:. Mulations, Gelucire® 50/13—Controlled release and increased bio- availability , Gattefossé PF , first ed., April 99, 3000 ex, 1999.

Peceol ™ Labrafac ™ lipophile WL 1349;. Solid state characterization, kinetic solubility, powder dissolution, stability, and pharmacokinetics were analyzed in rats. Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS).

It is able to self-emulsify on contact with aqueous media forming a fine dispersion i.e. Single excipient formulation system:. Gelucire ®50/13 (Stearoyl macrogol-32 glycerides) - bioavailability enhancement and sustained release Labrafil ®M2125 CS (Linoleyl macrogol-6 glycerides) - bioavailability enhancement Labrafil.

The average particle size of Gelucire 43/01 beads were not affected significantly by increasing Gelucire 43/01 ratio. The dissolution of poorly water soluble drugs may be significantly enhanced in a solid dispersion with hydrophilic lipid excipients, such as Gelucire 50/13 (85), Gelucire 44/14 (,93) compared to. The two numbers of Gelucires show their melting points and HLB values, respectively.

Gelucire ® 50/13 It is a non-ionic, water dispersible surfactant composed of well-characterized PEG-esters, a small glyceride fraction and free PEG. Particles from gas saturated solutions (PGSS) process was chosen for investigation as a manufacturing process for producing a …. Preparation of solid dispersions (SDs) and physical mixtures (PMs) Solubility enhancement of glibenclamide.

Several of these products listed are liquid or semi-solid, hence suitable for soft or hard shell capsules. However with a higher melting point and longer fatty acid chains it can have a release retarding effect when used at high concentration. USB2 US11/2,363 USA USB2 US B2 US B2 US B2 US A US A US A US B2 US B2 US B2 Authority US United States Prior art keywords method isotretinoin composition group consisting selected Prior art date Legal status (The legal status is an assumption and is not a legal conclusion.

Briefly, Precirol, 500 mg and Gelucire 50/13, at various concentrations (100, 150, 0, 250 and 650 mg) were transferred to a test tube. Legal notices - Terms and condition © Gattefossé People make our name. Gelucire 50/13 was provided by Gattefosse (Cedex, France) and has m.p.

Modulation of drug release. All other materials and reagents used were of analytical grade. SAXS analysis of the untreated sample shows a lamellar phase of1Å(figure2).Nosignaloftheacylglycerol fraction was detected.

Several of these products listed are liquid or semi-solid, hence suitable for soft or hard shell capsules. Between gelucire 50/13 and poloxamer 1 and to formulate the optimized solid dispersion into immediate release tablets. Priority to BE priority Critical Application filed by Galephar M/F filed Critical Galephar M/F Priority to PCT/BE01/ priority patent/WOA1/en Assigned to GALEPHAR M/F reassignment GALEPHAR M/F ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Gelucire 33/01, 39/01 y 43/01… Capryol ™ PGM Y 90;. US564B2 US13/525,857 USA US564B2 US 564 B2 US564 B2 US 564B2 US A US A US A US 564 B2 US564 B2 US 564B2 Authority US United States Prior art keywords isotretinoin pharmaceutical composition oral pharmaceutical composition mg Prior art date. A number of systems were prepared at five compositions (5, 10, , 30 and 40% w/w) of diclofenac/N-(2-hydroxyethyl) pyrrolidine salt and acidic diclofenac in PEG6000 and Gelucire 50/13, as.

MATERIALS and METHODS Materials Bosentan was received as gift sample from MSN Pharma, India. 50 °C and HLB 13. Self-emulsifies in aqueous fluid.

Gelucire 50/13 (semi-synthetic polyglycolized glycerides) was provided by Gattefosse, St.Priest, Cedex, France. Solubilizer for poorly-soluble APIs and bioavailability enhancer. Plurol Oleique ® CC497;.

Gelucire 50/13, and Gelucire 43/01 as lipid carriers. Solid self-emulsifying drug delivery systems (SEDDS) for medium chain triglycerides (Captex® 355, ABITEC) were developed using stearoyl polyoxyl glycerides (Acconon® C-50, ABITEC and Gelucire® 50/13, Gattefosse) as both solidifying and emulsifying agents. Modulation of drug release.

This can be advantageous for certain drugs or peptides and in. Gelucire ® 44/14 is a. Single excipient formulation system:.

GELUCIRE 50/13 and GELUCIRE 53/10 can be used according to our invention, but GELUCIRE 50/13 has been found to be particularly effective. The use of stearoyl macroglyceride (Gélucire® 50/13, Gattefosse) and soyabean oil allows to obtain a formulation with a dissolution profile similar to the reference (Roaccutane® mg, Roche). All other materials and reagents were of analytical grade of purity.

This self-emulsifying excipient that exists as a waxy semi-solid at ambient room temperature is a mixture of glyceryl and PEG 1500 esters of long-chain fatty acids and is listed in the European Pharmacopoeia as laurylmacrogolglycerides and in the. Lipid binder in melt processes. Application Water dispersible surfactant, Solubilizer, Bioavailability.

A mean particle size of approximately 250 nm was obtained for PVP K30-sirolimus nanoparticles. Main components of Gelucire® 50/13. As discussed previously, even though most Gelucires have T m > 37°C, (the most frequently used for SLN/NLC formulation up to now is Gelucire 50/13), their T m after processing to colloidal dimensions is expected to be decreased, leading to only partially crystallized lipid matrix.

Single excipient formulation system:. This is a purified, de-oiled, and granulated soy lecithin with a high phosphatidylcholine. Tocopheryl propylene glycol succinate, Sucroester 15, Gelucire 50/13, and Myrj 52.

Gelucire® 44/14 has achieved official USP-NF status with pending Food Additive (FCC) status. Product description Gelucire® 50/13 (stearoyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. The excipient is primarily a mix-ture of PEG 1500 mono- and diesters with.

Gelucires 44/14 (lauroyl macroglycerides), 50/13 (stearoyl macroglycerides), 62/05 (glyceryl behenate), and Labrasol were supplied by Gattefossé (Saint-Priest cedex, France). The average particle diameter of beads was found to be in the size range of 3.85 ± 0.13, 3.95 ± 0.21, and 3.87 ± 0.18 mm with varying drug/Gelucire 43/01 ratio from 1:5, 1:10, and 1:15, respectively (Table I). USB1 US09/623,213 USA USB1 US B1 US B1 US B1 US A US A US A US B1 US B1 US B1 Authority US United States Prior art keywords aqueous dispersion acid plasticizer lt dosage form Prior art date Legal status (The legal status is an assumption and is not a legal conclusion.

Single excipient formulation system:. People make our name. Labrafil® series (Table 2) consist of self-emulsifying excipients that may be in SEDDS / SMEDDS.

The formulation with labrafil or Gelucire® 50/02 are too lipophilic to give a good dissolution in water. Ranitidine HCl– lipid granules were prepared by the melt granulation technique and evaluated for in vitro floating and drug release. Its chemical name is Stearoyl macrogol-32 glycerides.

Gelucire® 44/14 is a versatile semi-solid lipidic excipient, proven to improve the bioavailability of poorly soluble drugs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS). The effect of variation in the Gelucire 50/13 concentration on the particle size of the Precirol SLN was also evaluated.

Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS). One preferred BCS class II drug is TEL. One excipient that has stimulated interest in lipid-based solid dispersion formulations is Gelucire 44/14 (Gattefosse Corp., St.

Craig, The physical characterisation of. Journal of Excipients and Food Chemicals , S.l., v. Precirol ® ATO 5 Vehículos Oleosos.

Other products, such as. Labrasol®, Gelucire® 44/14, Gelucire® 48/16, Gelucire® 50/13 and the Labrafil® series (Table 2) consist of self-emulsifying excipients that may be in SEDDS / SMEDDS. Modulation of drug release.

Application Water dispersible surfactant, Solubilizer, Bioavailability enhancer, Component of SELF, Matrix for modified release, Multiparticulates;. A stability study on samples was conducted for 3 months to evaluate the physical state of the drug and its dissolution in the formulation. Gelucire® 44/14, Gelucire® 48/16, Gelucire® 50/13.

Application of Acconon C-50 and Gelucire 50/13 as Both Solidifying and Emulsifying Agents for Medium Chain Triglycerides. Lipid binder in melt processes. N,O -CMCS (deacetylation degree 92.8%), was purchased from Heppe Medical Chitosan GmbH Halle (Saale), Germany and, according to manufacturer instructions, possesses a molecular weight in the.

ABITEC) were developed using stearoyl polyoxyl glycerides (Acconon®C-50, ABITEC and Gelucire®50/13, Gattefosse) as both solidifying and emulsifying agents. Legal notice - Terms and condition © Gattefossé People make our name. Sol id if yi ng an d emu ls if yi ng age nt s for.

Gelucire 50/13 was received as gift sample from Gattefosse, India, Poloxamer 1 was procured from Sigma Aldrich, India. Effect of variation in the Gelucire 50/13 concentration. Gelucire® 50/13 was a gift by Gattefossè (Milan, Italy).

Lipid binder in melt processes. Gelucire 39/01 y 43/01;. Dissolution studies were performed for melt granules of AET with Gelucire 50/13 (MG-AET) and solid dispersion with PVP (SDP) to differentiate dissolution performance.

Gelucire ® 50/13, Gattefosse) may serve as both. Gelucire® 50/13 is a well characterized excipient, supported by numerous publications and worldwide precedence of use including FDA IID listing. Solubilizer for poorly-soluble APIs and bioavailability enhancer.

Functionality Solubilizer for poorly-soluble APIs and bioavailability enhancer. CA1 CAA CA CA1 CA A1 C A1 CA A1 CA A CA A CA A CA A C A CA A CA A1 C A1 CA A1 Authority CA Canada Prior art keywords isotretinoin pharmaceutical composition contains group consisting mixtures Prior art date Legal status (The legal status is an assumption. Gelucire® 48/16, a novel carrier available in powder and pellet forms, is PEG-32 stearate, while, conventional gelucires, Gelucire® 44/14 and Gelucire® 50/13 are lauroyl polyoxyl-32glycerides NF and stearoyl polyoxyl-32 glycerides NF respectively.

Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS). Agente para enmascarar sabor. Mejoradores de la Biodisponibilidad.

Gelucire 50/13 is an excipient composed of fatty acid (C16 and C18) esters of glycerol, PEG esters and free PEG. It melts at approximately 50°C and has hydrophilic-lipophilic balance (HLB) value of 13 6, 7. Semi-solid bioavailability enhancer and sustained release agent.

Lauroglycol ™ FCC Y 90;. It is composed of fatty acid (majority of C 16 and C 18) esters of glycerol, PEG esters and free PEG. The aim of this study was to develop a formulation containing fenofibrate and Gelucire(®) 50/13 (Gattefossé, France) in order to improve the oral bioavailability of the drug.

The results revealed that the moderate amount of Gelucire 43/01 and ethyl cellulose. Curcumin (CUR), Tween® 85 and Tween® 80 were purchased by Sigma Aldrich (Milan, Italy). Application of Acconon C-50® and Gelucire 50/13® as Both Solidifying and Emulsifying Agents for Medium Chain Triglycerides Journal of Excipients and Food.